AU2017395700B2 - Methods for the administration of certain VMAT2 inhibitors - Google Patents

Methods for the administration of certain VMAT2 inhibitors Download PDF

Info

Publication number
AU2017395700B2
AU2017395700B2 AU2017395700A AU2017395700A AU2017395700B2 AU 2017395700 B2 AU2017395700 B2 AU 2017395700B2 AU 2017395700 A AU2017395700 A AU 2017395700A AU 2017395700 A AU2017395700 A AU 2017395700A AU 2017395700 B2 AU2017395700 B2 AU 2017395700B2
Authority
AU
Australia
Prior art keywords
nbi
disorder
vmat2
patient
hexahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017395700A
Other languages
English (en)
Other versions
AU2017395700A1 (en
Inventor
Haig P. Bozigian
Christopher F. O'Brien
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocrine Biosciences Inc
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62978647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2017395700(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of AU2017395700A1 publication Critical patent/AU2017395700A1/en
Application granted granted Critical
Publication of AU2017395700B2 publication Critical patent/AU2017395700B2/en
Priority to AU2022203327A priority Critical patent/AU2022203327A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
    • C07D455/06—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine containing benzo [a] quinolizine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Emergency Medicine (AREA)
AU2017395700A 2017-01-27 2017-10-10 Methods for the administration of certain VMAT2 inhibitors Active AU2017395700B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022203327A AU2022203327A1 (en) 2017-01-27 2022-05-17 Methods for the administration of certain VMAT2 inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762451605P 2017-01-27 2017-01-27
US62/451,605 2017-01-27
PCT/US2017/055877 WO2018140092A1 (en) 2017-01-27 2017-10-10 Methods for the administration of certain vmat2 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022203327A Division AU2022203327A1 (en) 2017-01-27 2022-05-17 Methods for the administration of certain VMAT2 inhibitors

Publications (2)

Publication Number Publication Date
AU2017395700A1 AU2017395700A1 (en) 2019-08-22
AU2017395700B2 true AU2017395700B2 (en) 2022-02-24

Family

ID=62978647

Family Applications (7)

Application Number Title Priority Date Filing Date
AU2017395700A Active AU2017395700B2 (en) 2017-01-27 2017-10-10 Methods for the administration of certain VMAT2 inhibitors
AU2017395702A Active AU2017395702B2 (en) 2017-01-27 2017-10-10 Methods for the administration of certain VMAT2 inhibitors
AU2017395703A Active AU2017395703B2 (en) 2017-01-27 2017-10-10 Methods for the administration of certain VMAT2 inhibitors
AU2017395704A Active AU2017395704B8 (en) 2017-01-27 2017-10-10 Methods for the administration of certain VMAT2 inhibitors
AU2017395701A Active AU2017395701B2 (en) 2017-01-27 2017-10-10 Methods for the administration of certain VMAT2 inhibitors
AU2022203201A Active AU2022203201B2 (en) 2017-01-27 2022-05-12 Methods for the administration of certain VMAT2 inhibitors
AU2022203327A Abandoned AU2022203327A1 (en) 2017-01-27 2022-05-17 Methods for the administration of certain VMAT2 inhibitors

Family Applications After (6)

Application Number Title Priority Date Filing Date
AU2017395702A Active AU2017395702B2 (en) 2017-01-27 2017-10-10 Methods for the administration of certain VMAT2 inhibitors
AU2017395703A Active AU2017395703B2 (en) 2017-01-27 2017-10-10 Methods for the administration of certain VMAT2 inhibitors
AU2017395704A Active AU2017395704B8 (en) 2017-01-27 2017-10-10 Methods for the administration of certain VMAT2 inhibitors
AU2017395701A Active AU2017395701B2 (en) 2017-01-27 2017-10-10 Methods for the administration of certain VMAT2 inhibitors
AU2022203201A Active AU2022203201B2 (en) 2017-01-27 2022-05-12 Methods for the administration of certain VMAT2 inhibitors
AU2022203327A Abandoned AU2022203327A1 (en) 2017-01-27 2022-05-17 Methods for the administration of certain VMAT2 inhibitors

Country Status (12)

Country Link
US (9) US20190381016A1 (enExample)
JP (16) JP7107950B2 (enExample)
KR (14) KR20230038601A (enExample)
CN (6) CN110740731A (enExample)
AU (7) AU2017395700B2 (enExample)
CA (5) CA3078719A1 (enExample)
EA (5) EA201991782A1 (enExample)
MX (6) MX394417B (enExample)
MY (5) MY195934A (enExample)
PH (6) PH12022553251A1 (enExample)
SG (3) SG11201906885TA (enExample)
WO (5) WO2018140096A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017075340A1 (en) 2015-10-30 2017-05-04 Neurocrine Biosciences, Inc. Valbenazine salts and polymorphs thereof
MA44127A (fr) 2015-12-23 2018-10-31 Neurocrine Biosciences Inc Procédés de synthèse pour la préparation de di(4-méthylbenzènesulfonate) de 2-amino-3-méthylbutanoate de (s)-(2r,3r,11br)-3-isobutyl-9,10-diméthoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1,-a]isoquinoléin-2-yl
KR20230038601A (ko) 2017-01-27 2023-03-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 ｖｍａｔ2 억제제의 투여 방법
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
CA3076000A1 (en) 2017-09-21 2019-03-28 Neurocrine Biosciences, Inc. High dosage valbenazine formulation and compositions, methods, and kits related thereto
MY198713A (en) 2017-10-10 2023-09-19 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
CN110621674B (zh) 2017-12-26 2022-03-29 苏州科睿思制药有限公司 一种Valbenazine二对甲苯磺酸盐的晶型及其制备方法和用途
AU2019261403B2 (en) 2018-04-25 2025-05-15 Shinkei Therapeutics, Inc. Tetrabenazine transdermal delivery device
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
US20200345663A1 (en) * 2018-06-10 2020-11-05 Axsome Therapeutics, Inc. Methods of modulating tetrabenazine metabolites plasma levels using bupropion
EP3836926A4 (en) 2018-08-15 2022-05-04 Neurocrine Biosciences, Inc. METHOD OF ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS
PH12021552745A1 (en) * 2019-05-09 2022-07-11 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
EP4013404A1 (en) * 2019-08-14 2022-06-22 F. Hoffmann-La Roche AG Methods of treating cancer
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
BR112022012246A2 (pt) * 2019-12-20 2022-08-30 Eisai R&D Man Co Ltd Uso de lemborexant para tratar insônia
AU2022302155A1 (en) 2021-06-30 2024-02-08 Neurocrine Biosciences, Inc. Valbenazine for use in the treatment of dyskinesia due to cerebral palsy
BR112023026691A2 (pt) 2021-06-30 2024-03-05 Neurocrine Biosciences Inc Valbenazina para uso no tratamento complementar de esquizofrenia
AU2022328761A1 (en) * 2021-08-16 2024-03-21 Foresee Pharmaceuticals Co., Ltd. Polymer depot compositions for sustained release delivery of vmat2 inhibitors
WO2023023593A1 (en) 2021-08-20 2023-02-23 Neurocrine Biosciences, Inc. Methods of screening for vmat2 inhibitors
US20230100844A1 (en) * 2021-09-10 2023-03-30 ATAI Life Sciences AG Ibogaine combination treatment
WO2023076568A1 (en) * 2021-10-29 2023-05-04 Neurocrine Biosciences, Inc. Valbenazine compositions
IL315181A (en) 2022-03-07 2024-10-01 Neurocrine Biosciences Inc Valbenazine, a vmat2 inhibitor, as a free base a tosylate or ditosylate salt, for use in the treatment of chorea associated with huntington's disease
EP4618961A1 (en) * 2022-11-16 2025-09-24 Foresee Pharmaceuticals Co., Ltd. Depot compositions for vesicular monoamine transporter 2 (vmat2) inhibitors
WO2025038959A1 (en) 2023-08-17 2025-02-20 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors
TW202521119A (zh) 2023-08-17 2025-06-01 美商紐羅克里生物科學有限公司 用於投與特定vmat2抑制劑之方法
WO2025096823A1 (en) 2023-11-01 2025-05-08 Neurocrine Biosciences, Inc. Improvement, maintenance or reduction of decline of motor function associated with huntington disease using valbenazine
WO2025188830A1 (en) 2024-03-06 2025-09-12 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015077521A1 (en) * 2013-11-22 2015-05-28 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
US20160030414A1 (en) * 2010-06-01 2016-02-04 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vmat 2
WO2016210180A2 (en) * 2015-06-23 2016-12-29 Neurocrine Biosciences, Inc. Vmat2 inhibitors for treating neurological diseases or disorders

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1068938A (en) 1910-11-07 1913-07-29 Gustav F Schulze Vehicle-apron.
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
JPS5283918A (en) 1976-01-01 1977-07-13 Wellcome Found Pharmaceutical composition
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
JPS5777697A (en) 1980-11-04 1982-05-15 Nippon Zoki Pharmaceut Co Ltd Physiologically active substance nsq
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
JPS57209225A (en) 1981-06-18 1982-12-22 Yamasa Shoyu Co Ltd Antitumor activity intensifier
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
JPS6028987A (ja) 1983-07-28 1985-02-14 Chugai Pharmaceut Co Ltd 新規ジゴキシン誘導体
HU196714B (en) 1984-10-04 1989-01-30 Monsanto Co Process for producing non-aqueous composition comprising somatotropin
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5204329A (en) 1990-06-11 1993-04-20 Du Pont Merck Pharmaceutical Company Treatment of organ transplantation rejection
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
AU6242096A (en) 1995-06-27 1997-01-30 Takeda Chemical Industries Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
ZA977967B (en) 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
WO1998014179A1 (en) 1996-10-01 1998-04-09 Cima Labs Inc. Taste-masked microcapsule compositions and methods of manufacture
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
DK0839525T3 (da) 1996-10-31 2004-11-29 Takeda Pharmaceutical Præparat med forlænget frigivelse
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
DE69719367T2 (de) 1996-12-20 2003-10-16 Takeda Chemical Industries, Ltd. Verfahren zur herstellung einer zusammensetzung mit verzoegerter abgabe
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
WO2000024399A1 (en) 1998-10-23 2000-05-04 Sepracor Inc. Compositions and methods employing r(-) fluoxetine and other active ingredients
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
AP2001002264A0 (en) 2000-08-30 2001-09-30 Pfizer Prod Inc Sustained release formulations for growth hormone secretagogues.
WO2003099011A1 (en) 2002-05-28 2003-12-04 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders
AU2003272608A1 (en) 2002-09-19 2004-04-08 University Of Utah Research Foundation Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson's disease
US7230097B2 (en) 2003-03-10 2007-06-12 Lupin Ltd. Process for preparation of 7-[α-Amino (4-hydroxyphenyl) acetamido]-3-substituted-3-cephem-4-carboxylic acid
GB0307259D0 (en) 2003-03-28 2003-05-07 Glaxo Group Ltd Process
GB2410947B (en) 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
CN106075435A (zh) 2004-06-04 2016-11-09 健泰科生物技术公司 用于治疗多发性硬化的方法
ES2825949T3 (es) 2004-09-30 2021-05-17 Vanda Pharmaceuticals Inc Métodos para administrar iloperidona
RU2007112409A (ru) 2004-10-28 2008-12-10 Вайет (Us) Одновременный прием тигициклина и дигоксина
WO2006053067A2 (en) 2004-11-09 2006-05-18 Prestwick Pharmaceuticals, Inc. Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders
DE602006004009D1 (de) 2005-08-06 2009-01-15 Cambridge Lab Ireland Ltd 3,11b-cis-dihydrotetrabanezin zur behandlung von schizophrenie und anderen psychosen
US20100076087A1 (en) 2005-10-06 2010-03-25 Auspex Pharmaceuticals, Inc. Methods of reduction of interpatient variability
AU2007317242B2 (en) 2006-11-08 2013-08-01 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto
GB0721669D0 (en) 2007-11-02 2007-12-12 Cambridge Lab Ireland Ltd Pharmaceutical compounds
HRP20151030T1 (hr) 2008-01-18 2015-11-06 Eisai R&D Management Co., Ltd. Kondenzirani derivat aminodihidrotiazina
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US20110053866A1 (en) 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
WO2011019956A2 (en) 2009-08-12 2011-02-17 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2463451A (en) 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
GB2463452A (en) 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
CA2736409C (en) 2008-09-18 2017-07-11 Auspex Pharmaceutical, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
US20100096319A1 (en) 2008-10-17 2010-04-22 General Electric Company Separator assembly
ES2792126T3 (es) 2009-04-06 2020-11-10 Vanda Pharmaceuticals Inc Método de tratamiento basado en polimorfismos del gen KCNQ1
WO2012153341A1 (en) 2011-05-12 2012-11-15 Arch Pharmalabs Limited A process for the preparation of iloperidone and pharmaceutically acceptable salts thereof
EP4345100A3 (en) 2012-09-18 2024-04-10 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
CA3158157A1 (en) 2012-12-18 2014-06-26 Vanda Pharmaceuticals Inc. Use of tasimelteon in the treatment of circadian rhythm disorders
EA201500801A1 (ru) * 2013-01-31 2016-01-29 Ауспекс Фармацетикалс, Инк. Бензохинолоновые ингибиторы vmat2
EA201691512A1 (ru) 2014-01-27 2017-01-30 Оспекс Фармасьютикалз, Инк. Бензохинолиновые ингибиторы везикулярного переносчика моноамина 2
WO2015120317A1 (en) 2014-02-07 2015-08-13 Neurocrine Biosciences, Inc. Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof
CA2938244A1 (en) 2014-02-07 2015-08-13 Auspex Pharamaceuticals, Inc. Novel pharmaceutical formulations
PT3936130T (pt) 2014-05-06 2024-04-17 Neurocrine Biosciences Inc Regime de dosagem de valbenazina para o tratamento de distúrbios de movimento hipercinéticos
EP3253752B1 (en) 2015-02-06 2023-08-16 Neurocrine Biosciences, Inc. [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
IL305352A (en) 2015-03-06 2023-10-01 Auspex Pharmaceuticals Inc Methods for treating abnormal movement disorders
WO2017075340A1 (en) 2015-10-30 2017-05-04 Neurocrine Biosciences, Inc. Valbenazine salts and polymorphs thereof
MA44127A (fr) 2015-12-23 2018-10-31 Neurocrine Biosciences Inc Procédés de synthèse pour la préparation de di(4-méthylbenzènesulfonate) de 2-amino-3-méthylbutanoate de (s)-(2r,3r,11br)-3-isobutyl-9,10-diméthoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1,-a]isoquinoléin-2-yl
EP4400171A3 (en) 2016-12-02 2024-09-11 Neurocrine Biosciences, Inc. Use of valbenazine for treating schizophrenia or schizoaffective disorder
KR20230038601A (ko) 2017-01-27 2023-03-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 ｖｍａｔ2 억제제의 투여 방법
WO2018164996A1 (en) 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
CA3057543A1 (en) 2017-04-01 2018-10-04 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine for use in the treatment a movement disorder
AU2018241940B2 (en) 2017-04-01 2023-09-28 Adeptio Pharmaceuticals Limited Dihydrotetrabenazine for use in the treatment a movement disorder
JOP20190239A1 (ar) 2017-04-19 2019-10-09 Neurocrine Biosciences Inc مركبات مثبطة لـ vmat2 وتركيبات منها
US20200179352A1 (en) 2017-04-26 2020-06-11 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
DK3426250T3 (da) * 2017-05-16 2022-05-16 Bow River LLC Behandling af en patient med et cyp3a4-substratlægemiddel, der er kontraindiceret til administration sammen med en stærk cyp3a4-inhibitor
US10857144B2 (en) * 2017-05-16 2020-12-08 Bow River LLC Methods of treatment
CA3076000A1 (en) 2017-09-21 2019-03-28 Neurocrine Biosciences, Inc. High dosage valbenazine formulation and compositions, methods, and kits related thereto
MY198713A (en) 2017-10-10 2023-09-19 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
EP3713938A1 (en) 2017-11-22 2020-09-30 Assia Chemical Industries Ltd Solid state form of valbenazine
EP3806856A1 (en) 2018-06-14 2021-04-21 Neurocrine Biosciences, Inc. Vmat2 inhibitor compounds, compositions, and methods relating thereto
EP3836926A4 (en) 2018-08-15 2022-05-04 Neurocrine Biosciences, Inc. METHOD OF ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS
PH12021552745A1 (en) 2019-05-09 2022-07-11 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
US10689380B1 (en) 2019-07-30 2020-06-23 Farmhispania S.A. Crystalline forms of valbenazine ditosylate
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160030414A1 (en) * 2010-06-01 2016-02-04 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vmat 2
WO2015077521A1 (en) * 2013-11-22 2015-05-28 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
WO2016210180A2 (en) * 2015-06-23 2016-12-29 Neurocrine Biosciences, Inc. Vmat2 inhibitors for treating neurological diseases or disorders

Also Published As

Publication number Publication date
MX394418B (es) 2025-03-24
CA3051834A1 (en) 2018-08-02
AU2017395704B8 (en) 2022-03-17
PH12019501740A1 (en) 2019-10-07
KR20230169457A (ko) 2023-12-15
PH12019501744A1 (en) 2019-09-30
MY195934A (en) 2023-02-27
EA201991780A1 (ru) 2021-10-26
KR20250078629A (ko) 2025-06-02
SG11201906885TA (en) 2019-08-27
KR20230170135A (ko) 2023-12-18
AU2017395704A1 (en) 2019-08-22
JP7090151B2 (ja) 2022-06-23
US20200093808A1 (en) 2020-03-26
US20200268724A1 (en) 2020-08-27
KR20250020722A (ko) 2025-02-11
AU2017395704B2 (en) 2022-02-24
SG11201906891RA (en) 2019-08-27
CA3051829A1 (en) 2018-08-02
KR20190108148A (ko) 2019-09-23
US20200338066A1 (en) 2020-10-29
MY191077A (en) 2022-05-30
MY203491A (en) 2024-06-30
US11040029B2 (en) 2021-06-22
MY199695A (en) 2023-11-18
CN116712434A (zh) 2023-09-08
KR20230170136A (ko) 2023-12-18
KR20190108146A (ko) 2019-09-23
US11439629B2 (en) 2022-09-13
CN110709071A (zh) 2020-01-17
KR20190108147A (ko) 2019-09-23
AU2017395703B2 (en) 2021-09-23
CN110740732A (zh) 2020-01-31
US10912771B1 (en) 2021-02-09
CA3051830A1 (en) 2018-08-02
AU2022203201B2 (en) 2023-11-02
WO2018140093A1 (en) 2018-08-02
WO2018140094A1 (en) 2018-08-02
CA3078719A1 (en) 2018-08-02
PH12019501732A1 (en) 2020-03-16
US20210169862A1 (en) 2021-06-10
JP2020536905A (ja) 2020-12-17
WO2018140096A1 (en) 2018-08-02
JP2024107169A (ja) 2024-08-08
CN110769826A (zh) 2020-02-07
MX2019008855A (es) 2019-09-11
US10874648B2 (en) 2020-12-29
MX393077B (es) 2025-03-24
CN111655034A (zh) 2020-09-11
JP2020514317A (ja) 2020-05-21
JP2022174345A (ja) 2022-11-22
EA202090676A1 (ru) 2021-10-08
KR20200126430A (ko) 2020-11-06
US20190381016A1 (en) 2019-12-19
JP2020505408A (ja) 2020-02-20
JP7107950B2 (ja) 2022-07-27
US10952997B2 (en) 2021-03-23
JP7199359B2 (ja) 2023-01-05
AU2017395702B2 (en) 2021-09-09
EA201991786A1 (ru) 2020-01-16
JP2024113134A (ja) 2024-08-21
CA3051832C (en) 2024-05-28
SG11201906883SA (en) 2019-08-27
AU2017395704A8 (en) 2022-03-17
AU2022203201A1 (en) 2022-06-02
CA3051834C (en) 2024-05-28
KR20190108149A (ko) 2019-09-23
JP2024107167A (ja) 2024-08-08
JP2022137219A (ja) 2022-09-21
MY202219A (en) 2024-04-17
US20210046060A1 (en) 2021-02-18
AU2017395702A1 (en) 2019-08-22
JP2023161033A (ja) 2023-11-02
WO2018140095A2 (en) 2018-08-02
AU2017395701B2 (en) 2024-02-15
KR20250020723A (ko) 2025-02-11
CA3051832A1 (en) 2018-08-02
JP7199360B2 (ja) 2023-01-05
AU2017395700A1 (en) 2019-08-22
MX2022007141A (es) 2022-07-19
US10857137B2 (en) 2020-12-08
JP2022174344A (ja) 2022-11-22
MX2019008854A (es) 2019-09-11
PH12019501734A1 (en) 2020-07-06
WO2018140095A3 (en) 2018-11-29
MX394415B (es) 2025-03-24
CN110740731A (zh) 2020-01-31
KR20250022883A (ko) 2025-02-17
AU2017395703A1 (en) 2019-08-22
MX2019008868A (es) 2019-09-16
WO2018140092A1 (en) 2018-08-02
US20200268725A1 (en) 2020-08-27
MX2020003462A (es) 2020-08-03
JP2024107168A (ja) 2024-08-08
PH12020550238A1 (en) 2021-02-15
JP2025146959A (ja) 2025-10-03
US20200268743A1 (en) 2020-08-27
JP2020514318A (ja) 2020-05-21
MX394417B (es) 2025-03-24
MX2019008853A (es) 2019-09-11
AU2017395701A1 (en) 2020-06-18
AU2022203327A1 (en) 2022-06-09
JP2022040408A (ja) 2022-03-10
JP2020505407A (ja) 2020-02-20
KR20230038601A (ko) 2023-03-20
KR20200066662A (ko) 2020-06-10
JP2022174343A (ja) 2022-11-22
US20210030742A1 (en) 2021-02-04
EA201991782A1 (ru) 2021-09-23
JP7199361B2 (ja) 2023-01-05
EA201991784A1 (ru) 2021-09-23
PH12022553251A1 (en) 2024-05-20

Similar Documents

Publication Publication Date Title
US10912771B1 (en) Methods for the administration of certain VMAT2 inhibitors
US11654142B2 (en) Methods for the administration of certain VMAT2 inhibitors
US10993941B2 (en) Methods for the administration of certain VMAT2 inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired
NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 10 OCT 2024 TO 10 MAY 2025 IN WHICH TO PAY A RENEWAL FEE HAS BEEN FILED

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY A RENEWAL FEE HAS BEEN EXTENDED TO 10 MAY 2025